PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Deucravacitinib - Psoriasis

PAD Profile : Deucravacitinib - Psoriasis

Keywords :
NICE, immunosuppressant, Disease modulating, Dermatology, TYK2 enzyme, Janus Kinas Inhibitor
Brand Names Include :
SOTYKTU

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
SA
ICB
BlueTeq
NICE
Comments :
No comments returned.

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves deucravacitinib as a treatment option in line with the recommendations made in NICE TA907, for treating moderate to severe plaque psoriasis.

 

Deucravacitinib for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

 

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More